Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 66 articles: HTML format Text format

Single Articles

May 2018
1. KANWAL R, Shukla S, Walker E, Gupta S, et al
   Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
   Cancer Lett. 2018 May 15. pii: S0304-3835(18)30339.
   PubMed     Text format     Abstract available
   
   
   
2. ABISOYE-OGUNNIYAN A, Lin H, Ghebremedhin A, Salam A, et al
   Transcriptional Repressor Kaiso Promotes Epithelial to Mesenchymal Transition and Metastasis in Prostate Cancer through Direct Regulation of miR-200c.
   Cancer Lett. 2018 May 8. pii: S0304-3835(18)30319.
   PubMed     Text format     Abstract available
   
   
   April 2018
3. SINGH SK, Lillard JW Jr., Singh R
   Title: Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
   Cancer Lett. 2018 Apr 17. pii: S0304-3835(18)30278.
   PubMed     Text format     Abstract available
   
   
   
4. CHANG AC, Chen PC, Lin YF, Su CM, et al
   Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system.
   Cancer Lett. 2018 Apr 5. pii: S0304-3835(18)30254.
   PubMed     Text format     Abstract available
   
   
   March 2018
5. OING C, Tennstedt P, Simon R, Volquardsen J, et al
   BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
   Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30196.
   PubMed     Text format     Abstract available
   
   
   
6. UTTER M, Chakraborty S, Goren L, Feuser L, et al
   Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
   Cancer Lett. 2018;423:28-35.
   PubMed     Text format     Abstract available
   
   
   February 2018
7. CHHABRA G, Singh CK, Ndiaye MA, Fedorowicz S, et al
   Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
   Cancer Lett. 2018 Feb 19. pii: S0304-3835(18)30158.
   PubMed     Text format     Abstract available
   
   
   
8. LIN W, Luo J, Sun Y, Lin C, et al
   ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
   Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30132.
   PubMed     Text format     Abstract available
   
   
   January 2018
9. MENG X, Vander Ark A, Daft P, Woodford E, et al
   Loss of TGF-beta signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
   Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30040.
   PubMed     Text format     Abstract available
   
   
   
10. LI X, Li J, Cai Y, Peng S, et al
    Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30053.
    PubMed     Text format     Abstract available
    
    
    
11. MITOBE Y, Takayama KI, Horie-Inoue K, Inoue S, et al
    Prostate cancer-associated lncRNAs.
    Cancer Lett. 2018 Jan 9. pii: S0304-3835(18)30034.
    PubMed     Text format     Abstract available
    
    
    December 2017
12. LIU S, Li X, Lin Z, Su L, et al
    SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.
    Cancer Lett. 2017;416:11-23.
    PubMed     Text format     Abstract available
    
    
    
13. HU F, Zhao Y, Yu Y, Fang JM, et al
    Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Cancer Lett. 2017;416:24-30.
    PubMed     Text format     Abstract available
    
    
    
14. CHENG MA, Chou FJ, Wang K, Yang R, et al
    Androgen receptor (AR) degradation enhancer ASC-J9((R)) in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cancer Lett. 2017 Dec 1. pii: S0304-3835(17)30763.
    PubMed     Text format     Abstract available
    
    
    November 2017
15. ZANG Y, Pascal LE, Zhou Y, Qiu X, et al
    ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30750.
    PubMed     Text format     Abstract available
    
    
    
16. LEE C, Whang YM, Campbell P, Mulcrone PL, et al
    Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Cancer Lett. 2017;414:205-213.
    PubMed     Text format     Abstract available
    
    
    
17. KUMAR S, Singh R, Malik S, Manne U, et al
    Prostate cancer health disparities: An immuno-biological perspective.
    Cancer Lett. 2017;414:153-165.
    PubMed     Text format     Abstract available
    
    
    
18. KOLLURU V, Pal D, Papu John AMS, Ankem MK, et al
    Induction of Plac8 promotes pro-survival function of autophagy in cadmium-induced prostate carcinogenesis.
    Cancer Lett. 2017;408:121-129.
    PubMed     Text format     Abstract available
    
    
    October 2017
19. GONZALEZ-CHAVARRIA I, Fernandez E, Gutierrez N, Gonzalez-Horta EE, et al
    LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30672.
    PubMed     Text format     Abstract available
    
    
    September 2017
20. QIN F, Zhang Y, Liu J, Li H, et al
    SLC45A3-ELK4 functions as a long non-coding chimeric RNA.
    Cancer Lett. 2017;404:53-61.
    PubMed     Text format     Abstract available
    
    
    
21. HOANG B, Ernsting MJ, Tang WS, Bteich J, et al
    Cabazitaxel-Conjugated Nanoparticles for Docetaxel-Resistant and Bone Metastatic Prostate Cancer.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30582.
    PubMed     Text format     Abstract available
    
    
    
22. EL-SAYED IY, Daher A, Destouches D, Firlej V, et al
    Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    Cancer Lett. 2017 Sep 19. pii: S0304-3835(17)30560.
    PubMed     Text format     Abstract available
    
    
    
23. BASHARI O, Redko B, Cohen A, Luboshits G, et al
    Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30535.
    PubMed     Text format     Abstract available
    
    
    August 2017
24. DATTA A, Kim H, Lal M, McGee L, et al
    Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30507.
    PubMed     Text format     Abstract available
    
    
    
25. CHEN J, Li L, Yang Z, Luo J, et al
    Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30491.
    PubMed     Text format     Abstract available
    
    
    
26. KANWAL R, Plaga AR, Liu X, Shukla GC, et al
    MicroRNAs in prostate cancer: Functional role as biomarkers.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30488.
    PubMed     Text format     Abstract available
    
    
    
27. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.
    Cancer Lett. 2017;406:71-80.
    PubMed     Text format     Abstract available
    
    
    
28. SHI X, Zhang X, Li J, Zhao H, et al
    PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Cancer Lett. 2017 Aug 7. pii: S0304-3835(17)30465.
    PubMed     Text format     Abstract available
    
    
    July 2017
29. LOGOZZI M, Angelini DF, Iessi E, Mizzoni D, et al
    Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Cancer Lett. 2017 Jul 8. pii: S0304-3835(17)30418.
    PubMed     Text format     Abstract available
    
    
    June 2017
30. GAO F, Alwhaibi A, Sabbineni H, Verma A, et al
    Suppression of Akt1-beta-catenin pathway in advanced prostate cancer promotes TGFbeta1-mediated epithelial to mesenchymal transition and metastasis.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30374.
    PubMed     Text format     Abstract available
    
    
    
31. LI Q, Ye L, Xin Z, Wang M, et al
    FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30375.
    PubMed     Text format     Abstract available
    
    
    May 2017
32. YAN F, Li X, Li N, Zhang R, et al
    Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy.
    Cancer Lett. 2017 May 18. pii: S0304-3835(17)30325.
    PubMed     Text format     Abstract available
    
    
    
33. DILLY SJ, Clark AJ, Marsh A, Mitchell DA, et al
    A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.
    Cancer Lett. 2017;393:16-21.
    PubMed     Text format     Abstract available
    
    
    April 2017
34. BRIZZOLARA A, Benelli R, Vene R, Barboro P, et al
    The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Cancer Lett. 2017 Apr 25. pii: S0304-3835(17)30285.
    PubMed     Text format     Abstract available
    
    
    March 2017
35. LIN SJ, Chou FJ, Li L, Lin CY, et al
    Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30217.
    PubMed     Text format     Abstract available
    
    
    
36. TAKAYAMA K, Inoue T, Narita S, Maita S, et al
    Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30216.
    PubMed     Text format     Abstract available
    
    
    
37. O'MALLEY J, Kumar R, Kuzmin A, Pliss A, et al
    Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.
    Cancer Lett. 2017 Mar 23. pii: S0304-3835(17)30199.
    PubMed     Text format     Abstract available
    
    
    
38. GUO C, Yeh S, Niu Y, Li G, et al
    Targeting Androgen Receptor versus Targeting Androgens to suppress Castration Resistant Prostate Cancer.
    Cancer Lett. 2017 Mar 18. pii: S0304-3835(17)30195.
    PubMed     Text format     Abstract available
    
    
    
39. KANG TS, Wang W, Zhong HJ, Dong ZZ, et al
    An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kappaB.
    Cancer Lett. 2017 Mar 16. pii: S0304-3835(17)30180.
    PubMed     Text format     Abstract available
    
    
    
40. EL BEZAWY R, Cominetti D, Fenderico N, Zuco V, et al
    miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30150.
    PubMed     Text format     Abstract available
    
    
    February 2017
41. MARTINEZ DE PINILLOS BAYONA A, Woodhams JH, Pye H, Hamoudi RA, et al
    Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: an in vitro study in 2D and 3D prostate cancer models.
    Cancer Lett. 2017 Feb 18. pii: S0304-3835(17)30127.
    PubMed     Text format     Abstract available
    
    
    January 2017
42. LIN LC, Gao AC, Lai CH, Hsieh JT, et al
    Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30041.
    PubMed     Text format     Abstract available
    
    
    
43. ZHANG L, Peng S, Dai X, Gan W, et al
    Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30021.
    PubMed     Text format     Abstract available
    
    
    December 2016
44. TONG D, Liu Q, Liu G, Xu J, et al
    Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30801.
    PubMed     Text format     Abstract available
    
    
    November 2016
45. WU H, Zhang L, Gao X, Zhang X, et al
    Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Cancer Lett. 2016 Nov 1. pii: S0304-3835(16)30667.
    PubMed     Text format     Abstract available
    
    
    October 2016
46. RAMALHO-CARVALHO J, Martins JB, Cekaite L, Sveen A, et al
    Epigenetic Disruption of miR-130a Promotes Prostate Cancer By Targeting SEC23B and DEPDC1.
    Cancer Lett. 2016 Oct 27. pii: S0304-3835(16)30649.
    PubMed     Text format     Abstract available
    
    
    
47. WU F, Dai X, Gan W, Wan L, et al
    Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30641.
    PubMed     Text format     Abstract available
    
    
    
48. TSAI YC, Chen WY, Siu MK, Tsai HY, et al
    Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30626.
    PubMed     Text format     Abstract available
    
    
    
49. JING P, Cao S, Xiao S, Zhang X, et al
    Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
    Cancer Lett. 2016 Oct 6. pii: S0304-3835(16)30610.
    PubMed     Text format     Abstract available
    
    
    September 2016
50. HORMAECHEA-AGULLA D, Gomez-Gomez E, Ibanez-Costa A, Carrasco-Valiente J, et al
    Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30564.
    PubMed     Text format     Abstract available
    
    
    
51. INGERSOLL MA, Miller DR, Martinez O, Wakefield CB, et al
    Statin Derivatives as Therapeutic Agents for Castration-Resistant Prostate Cancer.
    Cancer Lett. 2016 Sep 26. pii: S0304-3835(16)30550.
    PubMed     Text format     Abstract available
    
    
    June 2016
52. CALGANI A, Delle Monache S, Cesare P, Vicentini C, et al
    Leptin contributes to long-term stabilization of HIF-1alpha in cancer cells subjected to oxygen limiting conditions.
    Cancer Lett. 2016;376:1-9.
    PubMed     Text format     Abstract available
    
    
    
53. QIN F, Song Z, Chang M, Song Y, et al
    Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancer.
    Cancer Lett. 2016 Jun 17. pii: S0304-3835(16)30373.
    PubMed     Text format     Abstract available
    
    
    May 2016
54. WANG R, Lin W, Lin C, Li L, et al
    ASC-J9 suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Cancer Lett. 2016 May 24. pii: S0304-3835(16)30331.
    PubMed     Text format     Abstract available
    
    
    
55. LIU N, Mei L, Fan X, Tang C, et al
    Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
    Cancer Lett. 2016 May 11. pii: S0304-3835(16)30305.
    PubMed     Text format     Abstract available
    
    
    April 2016
56. DAS TP, Suman S, Papu John AM, Pal D, et al
    Activation of AKT negatively regulates the pro-apoptotic function of death-associated protein kinase 3 (DAPK3) in prostate cancer.
    Cancer Lett. 2016 Apr 25. pii: S0304-3835(16)30263.
    PubMed     Text format     Abstract available
    
    
    
57. CHOI H, Lee SH, Um SJ, Kim EJ, et al
    CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
    Cancer Lett. 2016 Apr 13. pii: S0304-3835(16)30254.
    PubMed     Text format     Abstract available
    
    
    
58. WEN S, Tian J, Niu Y, Li L, et al
    ASC-J9, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30203.
    PubMed     Text format     Abstract available
    
    
    March 2016
59. BARAKAT DJ, Mendonca J, Barberi T, Zhang J, et al
    C/EBPbeta regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion.
    Cancer Lett. 2016 Mar 8. pii: S0304-3835(16)30141.
    PubMed     Text format     Abstract available
    
    
    
60. ZHANG A, Zhang J, Kaipainen A, Lucas JM, et al
    Long non-coding RNA, a newly deciphered "code" in prostate cancer.
    Cancer Lett. 2016 Mar 7. pii: S0304-3835(16)30139.
    PubMed     Text format     Abstract available
    
    
    
61. HWANG JE, Joung JY, Shin SP, Choi MK, et al
    Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Cancer Lett. 2016;372:57-64.
    PubMed     Text format     Abstract available
    
    
    February 2016
62. SINGH S, Zheng Y, Jagadeeswaran G, Ebron JS, et al
    Deep sequencing of small RNA libraries from human prostate epithelial and stromal cells reveal distinct pattern of microRNAs primarily predicted to target growth factors.
    Cancer Lett. 2016;371:262-73.
    PubMed     Text format     Abstract available
    
    
    
63. CHEN JX, Li G, Wang H, Liu A, et al
    Dietary tocopherols inhibit PhIP-induced prostate carcinogenesis in CYP1A-humanized mice.
    Cancer Lett. 2016;371:71-8.
    PubMed     Text format     Abstract available
    
    
    January 2016
64. SHIAO SL, Chu GC, Chung LW
    Regulation of prostate cancer progression by the tumor microenvironment.
    Cancer Lett. 2016 Jan 28. pii: S0304-3835(15)00773.
    PubMed     Text format     Abstract available
    
    
    
65. FANG Z, Xu C, Li Y, Cai X, et al
    A feed forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression.
    Cancer Lett. 2016 Jan 22. pii: S0304-3835(16)30003.
    PubMed     Text format     Abstract available
    
    
    December 2015
66. KOUSHYAR S, Jiang WG, Dart DA
    Unveiling the potential of prohibitin in cancer.
    Cancer Lett. 2015;369:316-22.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: